Prostate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identifi ed 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3′ untranslated region of genes predicted to affect miRNA binding ( miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated ( P < 2.3 × 10 −5 ) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specifi c affi nity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affi nity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role.
, Sara Benlloch 
INTRODUCTION
Prostate cancer is the most common non-skin malignancy among men worldwide. In the United States, an estimated 233,000 new cases and 29,480 deaths were expected in 2014 ( 1 ) . Established risk factors for prostate cancer include advancing age, ethnicity, and a family history of the disease ( 2 ) . Men with a family history of prostate cancer have a 2-fold increased risk of developing the disease, usually with an earlier age of onset ( 3 ) . A signifi cant role for genetic factors has been confi rmed by genome-wide association studies (GWAS) and large-scale replication studies, which have already identifi ed 100 SNPs associated with prostate cancer risk ( 4, 5 ) . However, the identifi ed SNPs account for only a small proportion of the (33%) excess familial risk, suggesting that additional SNPs remain to be identifi ed ( 4 ) . miRNAs are short ∼19-24 nucleotide noncoding RNA molecules that posttranscriptionally regulate gene expression by www.aacrjournals.org Stegeman et al.
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cleaving or degrading mRNA and/or inhibiting its translation (6) (7) (8) . Most miRNA binding has been observed within the 3′ untranslated region (3′UTR) of their target genes, although there are examples of binding within mRNA coding regions ( 9 ) . As of March 2014, the miRBase database lists >2,570 mature miRNAs for humans. miRNAs are expressed in a tissue-and cell-specifi c manner with differential expression profi les in response to disease conditions, with many of these miRNA expression modulations contributing to disease progression (10) (11) (12) (13) (14) (15) . An impressive effort has been devoted to investigating miRNA dysregulation profi les in prostate cancer. Hence, miRNAs have emerged not only as potential biomarkers for prostate cancer but also as potential therapeutic targets (15) (16) (17) .
miRNAs negatively regulate their target mRNAs primarily through Watson-Crick base-pairing interactions ( 18, 19 ) . The most critical region for mRNA binding and repression is miRNA nucleotides 2 to 8, referred to as the miRNA seed site. Experiments have shown that genetic variations within the seed site or in the target mRNA at sites complementary to miRNA seed sites, referred to as miRSNPs, may reduce effectiveness or abolish miRNA-mediated repression, having functional consequences for cancer risk ( 20, 21 ) . For example, Liu and colleagues ( 22 ) recently reported that miRSNPs in ITGAv are associated with a decreased risk of prostate cancer. In another study assessing 61 putative miRSNPs in a Chinese population, three SNPs were associated with prostate cancer progression, whereas four SNPs were associated with prostate cancer-specifi c mortality ( 23 ) . However, all these studies have been conducted using small sample sizes and might not be refl ective of true positive association.
To further explore the genetic association of miRSNPs and to derive more reliable risk estimates of previously identifi ed prostate cancer risk miRSNPs, we investigated the association between 2,169 miRSNPs and prostate cancer risk and aggressiveness in 23 studies participating in the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium. This effort included 22,301 cases and 22,320 controls of European ancestry. We then validated the functional role of two prostate cancer risk miRSNPs, Kallikrein 3 ( KLK3 ) rs1058205 (T>C) and Vesicle-associated membrane protein 8 ( VAMP-8 ) rs1010 (A>G), as they were most strongly associated with disease aggressiveness. To our knowledge, this is the fi rst largescale investigation of the association between miRNA-related gene polymorphisms and prostate cancer risk.
RESULTS

Patient Characteristics
The characteristics of the study participants are presented in Table 1 . The mean age at diagnosis for cases (64.8 years) was older than the age at interview for controls (60.6 years). Cases (22.1%) were more likely to have a family history of prostate cancer compared with controls (13.9%). As expected, the majority of cases were diagnosed with tumors with a low (≤7) Gleason score (85.5%) that were localized (72.8%) and Figure 1 and Supplementary Table S1 show the results of the association analyses for 2,169 putative miRSNPs with prostate cancer risk. Twenty-fi ve miRSNPs had a minor allele frequency <0.01 in control samples. A total of 22 SNPs ( Table  2 ; Supplementary Fig. S1 ) representing 16 genes were associated with risk of prostate cancer after correction for multiple testing ( P < 2.3 × 10 −5 ). The most signifi cant association was observed for rs1058205 located within the KLK3 3′UTR with an OR of 0.86 (0.83-0.9), P = 1.7 × 10 −14
Association of miRSNPs with Prostate Cancer
. This SNP was previously identifi ed in a fi ne-mapping study ( 24 ) . Similarly, MDM4 rs4245739 was recently reported in the primary iCOGS analysis ( 4 ). Ten SNPs-rs2450975, rs3103353, and rs3127593 ( SLC22A2 ), rs1567669 ( NKX3-1 ), rs1010 ( VAMP8 ), rs1810126 ( SLC22A3 ), rs2647257 ( TET2 ), rs14082 and rs1043853 ( PDLIM5 ), and rs17664 ( ITGA6 )-were found in the genes/ regions previously implicated by prostate cancer GWAS studies. Ten SNPs-rs879161, rs7615039, and rs12492606 ( PHC3 ), rs311497 ( GMEB2 ), rs1530865 and rs2357637 ( PDK1 ), rs12573077 ( ARL3 ), rs7402 ( MCAT ), rs47340 ( TTLL12 ), and rs4233979 ( TMEM17 ) in seven genes ( PHC3, GMEB2, PDK1, ARL3, MCAT, TTLL12 , and TMEM17 ; Table 2 ), are at least 20 kb away from the previously reported index GWAS SNPs within the locus. Although GMEB2 and ARL3 have been previously reported, these seven genes have not been mapped by previous GWAS as per the National Human Genome Research Institute catalog in November 2014 ( 25 ) .
In secondary analysis, seven SNPs showed signifi cant differences in per-allele ORs between aggressive and nonaggressive disease (Supplementary Table S2 ). The most signifi cant difference was observed for the KLK3 rs1058205 SNP; however, this SNP was more strongly associated with nonaggressive disease, which is in line with previous reports on other Kallikrein SNPs ( 24 , 26 ) . Interestingly, only two SNPs, rs1010 in VAMP8 and rs311497 in GMEB2 , showed stronger association with aggressive disease. The rs1567669 SNP ( NKX3-1 ) was associated with PSA levels in the patient cohort (Supplementary Table S3 ). Six SNPs (rs1043853, rs1058205, rs14082, rs2450975, rs3103353, and rs3127593), including KLK3 rs1058205, were marginally associated with PSA levels in controls (Supplementary Table  S3 ). Six SNPs showed a trend with respect to age at diagnosis, including rs1058205, rs1043853, rs12492606, rs14082, rs7615039, and rs879161 (Supplementary Table S4 ).
Gene Expression and eQTL Analysis
Using the Oncomine (Compendia Bioscience) analysis tool, we compared the expression levels of the 16 genes harboring 22 signifi cant miRSNPs. Using the Grasso dataset ( 27 ) of 59 tumor and 28 nontumor samples, expression of 7 genes was found to be deregulated in prostate cancer versus matched benign tissue analysis ( Fig. 2 ) . We found KLK3 and VAMP8 to be the second-and seventh-highest deregulated genes within the 16 genes analyzed.
We undertook a cis-eQTL analysis of the 22 prostate cancerassociated miRSNPs using The Cancer Genome Atlas (TCGA) data. Three SNPs [rs1058205 ( KLK3 ), rs1530865, and rs2357637 Table S5 ). None of the other SNPs were associated with transcript levels of the gene harboring the SNP.
Functional Validation of the KLK3 rs1058205 and VAMP8 rs1010 miRSNPs
Using a range of computational prediction algorithms, we identifi ed three miRNAs predicted to have differences in binding affi nity between the KLK3 rs1058205 SNP-alleles. SNPinfo ( 29 ) and mirsnpscore ( 30 ) predicted miR-219-1-3p to target the T-allele, MicroSNiPer ( 31 ) and mirsnpscore also predicted miR-3162-5p to target the T-allele, and MicroSNiPer and mirsnpscore predicted miR-4278 to target the C-allele. Two miRNAs were predicted to have differences in binding affi nity between the VAMP8 rs1010 SNP-alleles. SNPinfo predicted both miR-103 and miR-370-5p to target the A-allele (sense strand = T-allele).
Reporter vector assays were then used to test the validity of the in silico-predicted miRNA binding potential to their target genes with specifi c genotype. For KLK3 rs1058205 SNP, miRNA miR-3162-5p induced an approximate 29% ( P = 0.048) decrease in luciferase levels for the T-allele compared with the C-allele, suggesting that miR-3162-5p has specifi c affi nity for the T-allele ( Fig. 3A ) . No signifi cant changes were observed for miR-219-1-3p or miR-4278 with either of the alleles for SNP rs1058205 (Supplementary Fig. S2A and S2B). For VAMP8 rs1010 (A>G), though miR-370-5p induced a change in luciferase activity for both alleles, the decrease in luciferase levels for the A-allele was approximately 2-fold ( P = 0.0067) stronger than for the G-allele ( Fig. 3B ). Although miR-103 was found to regulate VAMP8 expression, it showed comparable results for both alleles ( Supplementary Fig. S2C ).
Expression of miR-3162-5p and miR-370-5p in Prostate Cancer
Though previously reported in melanoma, breast cancer, and cervical cancer (with expression upregulated in cervical cancer; refs. 32-34 ), prostatic expression for miR-3162-5p has not been determined. However, the miR-3162-5p gene is located within intron seven of the oxysterol binding protein gene, which is known to be expressed in the normal and cancerous prostate (32) (33) (34) (35) . Using qPCR, we specifi cally confi rmed miR-3162-5p expression in a range of cancerous and noncancerous prostatic cell lines ( Supplementary  Fig. S3A ) as well as in patient tissue samples ( Supplementary  Fig. S3B ). miR-3162-5p was detected in all the model cell lines and patient samples with varying expression levels. Prostatic expression for miR-370-5p has been reported previously to be upregulated in cancer ( 17 , 36 Figure 3 . miR-3162-5p directly targets the KLK3 rs1058205 SNP T-allele, and miR-370-5p targets the VAMP8 rs1010 SNP A-allele with greater affi nity. Following overexpression with miR-3162-5p, reporter vector assays demonstrated an approximate 29% decrease in luciferase levels ( P = 0.048) for the KLK3 rs1058205 SNP T-allele compared with the C-allele (A). Overexpression of miR-370-5p resulted in a change in luciferase activity for both VAMP8 rs1010 SNP variants with the decrease for the A-allele approximately 2-fold ( P = 0.0067) stronger than for the G-allele (B). Mean ± SD, n = 3. *, P < 0.05; **, P < 0.01. 
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Regulation of KLK3 mRNA and Protein Levels by miR-3162-5p
Given the importance of KLK3/PSA as a serum biomarker for prostate cancer, we further characterized the miR-3162-5p and KLK3 rs1058205 SNP interaction, to determine whether miR-3162-5p was able to affect endogenous KLK3 mRNA and protein levels in cell lines using LNCaP cells homozygous TT for the rs1058205 SNP. With reference to the negative control miRNA mimic, overexpression of miR-3162-5p resulted in a 25% decrease in KLK3 mRNA ( P = 0.016) as determined using qPCR analysis ( Fig. 4A ) .
We then assessed whether miR-3162-5p was able to affect endogenous KLK3 protein levels. With reference to the negative control miRNA mimic, overexpression of miR-3162-5p resulted in a 32% decrease in cellular KLK3 protein ( P = 0.007) as determined using Western blot analysis ( Fig. 4B and C ) .
DISCUSSION
In this study, we investigated the association between 2,169 putative miRSNPs and prostate cancer risk in a large sample set including 22,301 cases and 22,320 controls of European ancestry. We identifi ed 22 SNPs within the 3′UTR of the 16 genes to be associated with risk of prostate cancer, 7 of which, although within the previously identifi ed GWAS locus, were not previously mapped by the GWAS studies. The most signifi cant association was for the KLK3 rs1058205 SNP, previously identifi ed to be associated with prostate cancer risk in a recent study ( 24 ) .
Seven of these SNPs, including KLK3 (rs1058205) and VAMP8 (rs1010), a gene for which little is known about its prostatic function, showed signifi cant differences between aggressive and nonaggressive disease. As expected, these results were not as robust due to the small sample size in the aggressive disease subcohort. Thus, it was not surprising that, as has been the case for many previously GWAS-identifi ed SNPs ( 37 ), we could identify only two SNPs to be more signifi cantly associated with aggressive disease.
Using Oncomine, we compared the expression levels of these 16 genes in a dataset consisting of 59 tumor and 28 nontumor samples, revealing the expression of seven of these genes to be deregulated in prostate cancer. KLK3 was the second most deregulated gene. We then chose to validate the functional role of the KLK3 rs1058205 SNP, it being the most signifi cant miRSNP identifi ed. We demonstrated that miR-3162-5p has specifi c affi nity for the KLK3 rs1058205 T-allele. Our results support the 
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emerging "miRNA network" that contributes to prostate cancer by regulating kallikrein and non-kallikrein genes ( 38 ) .
As prostatic expression for miR-3162-5p had not been determined previously, we confi rmed its expression in a range of cancerous and noncancerous prostatic cell lines and in patient tissue samples. It is interesting to note that prostate cancer PC3 cell lines with the highest miR-3162-5p expression do not produce any endogenous KLK3. In previous studies, this differential expression has been attributed to absence of an androgen receptor in the PC3 cell lines because KLK3 expression is androgen dependent in other prostate cancer cell lines. However, its regulation by miR-3162-5p could be an alternative regulatory mechanism and rationale for no KLK3 expression in these cells.
KLK3 is also referred to as a prostate-specifi c antigen (PSA), as it is expressed at orders of magnitude higher in the prostate compared with other tissues ( 39 ) . As KLK3 serum levels are often elevated in prostate cancer, largely due to leakage associated with a loss of tissue architecture, KLK3 is thus utilized as the major serum biomarker for this disease ( 39, 40 ) . Given the potential importance of KLK3 for prostate cancer diagnosis, we further characterized the miRNA-KLK3 rs1058205 interaction, demonstrating that miR-3162-5p is able to cause a decrease in KLK3 mRNA and KLK3 protein expression in LNCaP cells homozygous for the T-allele. Interestingly, the KLK3 rs1058205 SNP was associated with PSA levels in the control population (Supplementary Table S3 ), which may refl ect some effects of strong regulatory factors (such as miRNA), exerting genotypespecifi c effects for this locus. The rs1058205 SNP, in addition to other PSA-associated SNPs, may therefore have implications for PSA-based diagnosis, hence requiring adjustments to PSA ranges for specifi c genotype. Furthermore, as KLK3 belongs to a family of 15 homologous genes, it would be important to consider potential additional effects of miR-3162-5p miRNA on other kallikrein and non-kallikrein targets in future studies.
The KLK3 rs1058205 T-allele was previously shown to be associated with increased prostate cancer risk ( 24 ) . Here, we demonstrate that decreased KLK3 expression induced by miR-3162-5p targeting of the T-allele represents a mechanism by which the rs1058205 T-allele may be associated with increased prostate cancer risk. Interestingly, it has been shown that more aggressive prostate tumors have lower tissue levels of KLK3 ( 41 ) . One mode via which KLK3 may act in a protective capacity in prostate cancer is through inhibition of angiogenesis ( 42, 43 ) . Although the full mechanism is unclear, the antiangiogenic effect of KLK3 has been attributed to its proteolytic function on various angiogenic and antiangiogenic proteins ( 44, 45 ) . However, due to its additional proteolytic function and its subsequent potential to target components of cell-cell adhesion and the extracellular matrix, high levels of KLK3 have also been proposed as a risk for prostate cancer. It is therefore possible that the effects of KLK3 on tumor development are stage-specifi c, with low KLK3 contributing to increased localized tumor growth (as observed in genetic risk analysis), whereas high KLK3 poses a risk at later metastatic stages of tumor development.
The VAMP8 rs1010 SNP was also selected for functional validation due to its signifi cant association with aggressive prostate cancer, where miR-370-5p was found to have greater affi nity for the VAMP8 rs1010 A-allele versus the minor G-allele. Interestingly, prostatic expression for miR-370-5p has been reported previously to be upregulated in cancer ( 17 , 35 ) .
To our knowledge, this is the fi rst study to report an association and mechanism of action between a VAMP8 miRSNP and prostate cancer risk. VAMP8 is an integral membrane protein that is involved in the fusion of synaptic vesicles with the presynaptic membrane. It also plays a complex role in the control of granule secretion, transport vesicle traffi cking, phagocytosis, and endocytosis ( 46, 47 ) . Loss of VAMP8 has been shown to affect glucose metabolism, energy expenditure, and insulin sensitivity in mice ( 48 ) . Though a direct role of VAMP8 in cancer is unknown, its ability to infl uence glucose metabolism and energy expenditure makes it a potential candidate in carcinogenesis, in relation to the shift in cellular metabolism from oxidative phosphorylation to glycolysis (the Warburg effect) that occurs in cells undergoing malignant transformation ( 48, 49 ) . Hence, the role of VAMP8 may be important for prostate cancer. The VAMP8 rs1010 SNP was previously associated with risk for early onset myocardial infarction ( 50 ) and is in high linkage disequilibrium (LD; r No functional relevance has been assigned to the rs10187424 SNP. In the current study, we demonstrated that miR-370-5p has greater affi nity for the VAMP8 rs1010 A-allele, thus identifying the likely causal variant behind the GWAS marker SNP. Nevertheless, the possibility of another functional variant in LD with rs1010, or any other putative functional miRSNPs (including KLK3 ) identifi ed in our study cannot be ruled out. Larger sample sizes are now required to provide additional power to assess true independence and/or the effect of these SNPs as modifi ers of the unknown functional variants and/ or top risk GWAS SNPs using conditional regression and/or haplotype analysis. Furthermore, it should be noted that the size effects of these variants are very small though comparable with previous GWAS studies. Thus, once independent causal variants or haplotypes at each of the known GWAS loci are identifi ed, it would be interesting to undertake risk score calculations to assess the additive effects of all GWAS-identifi ed SNPs, including the miRSNPs identifi ed in our study.
Although our analysis has identifi ed several miRSNPs previously not reported by the GWAS analysis, functional validation of these variants is required. Our eQTL analysis did not yield any signifi cant results for genotype-mRNA expression correlation except for an SNP in SLC22A2 , which is not surprising given that the miRNA machinery might not affect the mRNA levels in situ but will only inhibit the translation of these genes. Future studies are warranted to correlate genotypes with protein expression using immunohistochemistry and/or Western blot analysis. Additional functional studies may further clarify the role of these novel miRSNPs in prostate cancer etiology.
In conclusion, our study has identifi ed putative functional SNPs associated with prostate cancer risk in several genes that further show differential expression in tumor versus normal tissue from patients with prostate cancer. The functional validation for the rs1058205 and rs1010 miRSNPs herein provides increasing evidence that miRSNPs may be associated with prostate cancer risk. 
METHODS
Study Populations
The Collaborative Oncological Gene-environment Study (COGS) is a large collaborative effort among different consortia, including PRACTICAL, to evaluate genetic variants for associations with the risk of prostate, ovarian, and breast cancers. Details of the study have been reported previously ( 4 ). Briefl y, 32 studies participating in the PRACTICAL consortium contributed samples from 25,074 prostate cancer cases and 24,272 controls to COGS. The majority of studies were nested, population-based, or hospital-based case-control studies. Individuals were excluded from the study based on strict quality control criteria, including overall genotype call rate <95%, genotypically non-European origin, samples that were XX or XXY and therefore not genotypically males, or samples not concordant with previous genotyping within PRACTICAL. The present analysis included 44,621 samples (22,301 cases and 22,320 controls) of European ancestry. Demographic and clinical information on study participants, including age at diagnosis, Gleason score, stage of disease, PSA, and cause of death, was obtained through in-person interviews or medical or death records. Aggressive disease was defi ned as Gleason score ≥8, PSA >100 ng/mL, disease stage of "distant" (outside the pelvis), or prostate cancer-associated death. Study was approved by each Institutional Review Board, and informed consent was obtained from each participant. Patient studies were conducted in accordance with the Declaration of Helsinki.
miRSNP Selection and Genotyping
A total of 2,169 miRSNPs within the 3′UTRs of the cancer-associated genes were selected for genotyping. An SNP was selected if differential miRNA binding potential for the alternative alleles was predicted by at least two of four algorithms: (i) Mirsnpscore ( 30 ) , or if genotypes were discrepant in more than 2% of duplicate samples.
cis-eQTL Analysis
For each index miRSNP, we retrieved all the correlated ( r 2 ≥ 0.8) variants in European populations from 1000 Genomes using SNAP ( 28 ) . The preprocessed (Level 2) germline genotypes of the index or correlated SNPs were downloaded from the TCGA data portal, and the expression levels of genes harboring these SNPs were obtained via the cBio Portal for Cancer Genomics. Using standard QC analysis, 6 samples were removed either due to discordant sex information (X-chromosome homozygosity rate between 0.2 and 0.8) or due to a heterozygosity rate >3 SDs from the mean. An additional 45 individuals were removed due to ethnic heterogeneity as calculated using principal component analysis. Data from 178 Caucasian individuals were used for the fi nal genotype expression correlation analysis by the Kruskal-Wallis test using IBM SPSS Statistics (version 22).
miRNA Target Reporter Vector Assays
To assess the validity of in silico predictions for miRNA-mRNA affi nity, miRNA target luciferase reporter vector assays were performed. Reporter vectors were constructed for the major and minor SNP-allele variants for both KLK3 and VAMP8 using the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) for KLK3 constructs, and the pMIR REPORT vector (Ambion) for VAMP8 constructs. (Portions of KLK3 and VAMP8 pertaining to predicted miRNA binding regions were synthesized by Integrated DNA Technologies.) LNCaP cells were cotransfected with vector and mir Vana miRNA Mimics (Life Technologies) using FuGENE transfection reagent (Promega) and then analyzed 24 hours later using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Luciferase levels were normalized against Renilla coexpressed from the same vector or against the β-galactosidase derived from coexpression with a second vector measured using Galacto-Light (Tropix) for VAMP8 . For KLK3 , on the day of transfection, cells were cultured in 1% charcoal-stripped serum for the remainder of the experiment to induce lower levels of endogenous KLK3 to minimize the impact of miRNA mimicendogenous KLK3 binding on reporter vector assay sensitivity. A negative control mir Vana miRNA Mimic, Negative Control #1 (Life Technologies), was used for analysis alongside candidate miRNAs. A single experiment consisted of each miRNA/vector treatment cultured in triplicate. Three independent experiments were conducted in total.
RT-qPCR Analysis to Assess miRNA Expression
miRNA was extracted as total RNA from cell lines (LNCaP, LAPC4, DUCAP, DU145, PC3, 22Rv1, RWPE1, and BPH1) obtained from the ATCC unless otherwise stated (see Acknowledgments) using TRIzol reagent (Life Technologies). Cell line authentication (short tandem repeat profi ling) was performed by either the Queensland Institute of Medical Research (Brisbane, Queensland, Australia) or DDC Medical (Fairfi eld, Ohio).
Formalin-fi xed and paraffi n-embedded (FFPE) blocks from prostate tumors and their adjacent noncancer prostate were obtained from the Australian Prostate Cancer BioResource tumor bank. Tissue blocks containing the tumor cells were serially sectioned (20-μm sections) and transferred to glass slides. Slides were stained with methyl green, and the tumor areas were marked by a pathologist. Marked areas were then manually microdissected under a microscope using a sterile injection needle (size, 0.65 × 25 mm). RNA was extracted using the miRNeasy FFPE Kit (Qiagen).
To assess expression, reverse transcription and qPCR were performed using the TaqMan MicroRNA Reverse Transcription Kit and TaqMan MicroRNA Assays (Life Technologies). The small nuclear RNA RNU24 was used as an endogenous quantitative normalization control ( 16 ) . Relative expression levels were calculated using the comparative C t method. As TaqMan MicroRNA Assays were not commercially available for miR-3162-5p, we designed in-house assays for miR-3162-5p (Supplementary Methods S1) following the TaqMan methodology ( 51 ).
RT-qPCR and Western Blot Analysis to Assess KLK3 mRNA and Protein Expression
LNCaP cells were plated at 150,000 cells per well on a 6-well plate overnight, then cultured in 1% charcoal-stripped serum (for the remaining duration of the experiment), and transiently transfected with 30 nmol/L of mir Vana miRNA Mimics using Lipofectamine RNAiMAX transfection reagent (Life Technologies) followed by a treatment with 10 nmol/L dihydrotestosterone (DHT) to stimulate KLK3 expression via the androgen receptor pathway. Total RNA was isolated after 24 hours incubation after DHT stimulation using the RNAeasy Mini Kit (Qiagen) and assessed for quality and yield using a Nanodrop ND-1000 spectrophotometer. RNA was reverse transcribed using oligo dT primers and 500 ng of total RNA. qPCR for KLK3 was then performed using the SYBR Green PCR Master Mix (Life Technologies) for each sample in triplicate with β-actin used as an endogenous quantitative normalization control. Relative expression levels were calculated using the comparative C t method. Primers were synthesized by Integrated DNA Technologies. Primer sequences for KLK3 were as follows: forward primer 5′-agtgcgagaagcattcccaacc-3′, reverse primer 5′-ccagcaagatcacgcttttgttcct-3′. Primer sequences for 
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β-actin were as follows: forward primer 5′-gcgttacaccctttcttgacaaaacc t-3′, reverse primer 5′-gctgtcaccttcaccgttcca-3′.
Total protein was isolated using SDS lysis buffer (1% SDS, 5% glycerol, 10 nmol/L Tris, Roche Complete protease inhibitor), concentration was assessed via the bicinchoninic acid (BCA ) method, and 10 μg of total protein was run using standard techniques on a 12% resolving polyacrylamide gel. Western blotting was performed using standard techniques with primary antibodies, including Rb anti-KLK3 (0.6 μg/mL; Dako; A0562) and Rb anti-β-actin (0.6 μg/mL; Abcam; ab25894). Western blots were imaged on an Odyssey Imaging System (LI-COR Biosciences) using fl uorescently labeled secondary antibodies (Alexa Fluor 680 and 790; Invitrogen) with protein band intensities analyzed via densitometry using Odyssey Imaging System software.
Statistical Analysis
Demographic, clinical, and mortality information was summarized by mean (SD) and number (%). Ethnic groups were defi ned based on a subset of 37,000 uncorrelated markers that passed quality control (including ∼1,000 selected as ancestry informative markers). The COGS data were combined with the three Hapmap2 populations, and multidimensional scaling was used to identify and exclude ethnic outliers ( 4 ) . After exclusion of ethnic outliers, principal component analyses were carried out for Europeans. The fi rst six principal components were used to control for population substructure as additional principal components did not reduce infl ation further ( 4 ) . Associations between individual SNPs and prostate cancer risk or aggressive disease were evaluated using logistic regression models to estimate per minor allele ORs and 95% CIs. Associations between individual SNPs and prostate cancer risk were also evaluated in a similar manner for different age categories. The associations between SNP genotypes and PSA level were assessed using linear regression, after log-transformation of PSA level to correct for skewness. Analyses were performed using SPSS and R. All models included study site and principal components as covariates.
Unless otherwise stated, for all other analyses, three independent experiments were conducted with results presented as mean ± SD, and analyzed using a Student t test, with a P value of <0.05 considered statistically signifi cant for the functional studies.
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